Wecare Probiotics achieves CNAS/ISO 17025 accreditation, enhancing quality standards in probiotic testing for global health solutions. This milestone certifies that the laboratory’s technical competence, quality management systems, and testing procedures meet rigorous global standards, further strengthening trust and reliability across the health and nutrition industry.

We will attend Natural Products Expo West 2026 at Anaheim Convention Center (Mar 4-6), Booth 3717, showcasing our flagship strain BC99 with over 100°C heat resistance

WECARE International Probiotics & Health Conference 2026 will be held in Suzhou on March 20, focusing on probiotics and sports nutrition, with registration now open for global peers.

A specific probiotic strain, Akk11, may be reshaping the therapeutic paradigm for Parkinson’s disease (PD). Two recent high-impact studies from Wecare Research Institute show that this strain not only mitigates PD-related constipation but also ameliorates depressive phenotypes—two frequently comorbid, clinically intractable non-motor symptoms (NMS).

Parkinson's disease (PD) is not just a movement disorder; it also involves significant non-motor symptoms, particularly constipation and depression. These symptoms, which affect a large portion of patients, are closely tied to dysfunction in the gut-brain axis. Constipation is present in up to 70% of PD patients, while depression is also highly prevalent.

Gut microbiota balance plays a key role in metabolic health, and Akkermansia muciniphila (AKK) — a “next-generation probiotic” discovered in 2004 — has emerged as a promising contributor. Studied in over 70 countries with more than 1,700 publications and 600 patents, AKK supports glucose regulation, gut barrier integrity, and inflammation control, linking gut health to metabolic and immune function.